Menerba

Menerba, also known as MF101, is an experimental drug that is being developed for the treatment of menopausal symptoms. It is a botanical drug that is derived from 22 different herbs. Menerba is being developed by Bionovo, a pharmaceutical company based in Emeryville, California.

History

Menerba was initially developed as a potential treatment for hot flashes and other symptoms associated with menopause. The drug was designed to selectively bind to estrogen receptors in the body, which are believed to play a key role in the development of menopausal symptoms.

In 2007, Bionovo announced that it had completed a Phase 2 clinical trial of Menerba. The trial involved 217 women and found that the drug was effective in reducing the frequency and severity of hot flashes. The company also reported that Menerba was well-tolerated and did not cause any significant side effects.

Mechanism of Action

Menerba works by selectively binding to estrogen receptors in the body. This binding action is believed to help regulate the body's temperature, which can help to reduce the frequency and severity of hot flashes. Menerba is also thought to have anti-inflammatory and antioxidant properties, which may further contribute to its therapeutic effects.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Menerba. These trials have generally found that the drug is well-tolerated and can effectively reduce the frequency and severity of hot flashes in menopausal women.

Future Development

As of 2021, Menerba is still in the development stage and has not yet been approved for use by the Food and Drug Administration (FDA). However, Bionovo continues to conduct research and clinical trials in an effort to further evaluate the drug's safety and efficacy.

See Also

• Menopause
• Estrogen receptor
• Hot flash
• Bionovo

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia